Multimodality treatment in high-risk and very high-risk prostate cancer : outcomes from international phase III randomized controlled trials
| Errataetall: |
CommentOn: J Clin Oncol. 2021 Mar 1;39(7):787-796. - PMID 33471548 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:198 |
|---|---|
| Enthalten in: |
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al - 198(2022), 10 vom: 22. Okt., Seite 962-965 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Multimodale Therapieansätze beim Hochrisikoprostatakarzinom – was wann? |
|---|
| Beteiligte Personen: |
Mathier, Etienne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase III |
|---|
| Anmerkungen: |
Date Completed 29.09.2022 Date Revised 25.10.2022 published: Print-Electronic CommentOn: J Clin Oncol. 2021 Mar 1;39(7):787-796. - PMID 33471548 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00066-022-01968-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342540661 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342540661 | ||
| 003 | DE-627 | ||
| 005 | 20231226014343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00066-022-01968-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342540661 | ||
| 035 | |a (NLM)35732920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Mathier, Etienne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multimodality treatment in high-risk and very high-risk prostate cancer |b outcomes from international phase III randomized controlled trials |
| 246 | 3 | 3 | |a Multimodale Therapieansätze beim Hochrisikoprostatakarzinom – was wann? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2022 | ||
| 500 | |a Date Revised 25.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Clin Oncol. 2021 Mar 1;39(7):787-796. - PMID 33471548 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Comment | |
| 700 | 1 | |a Heusel, Astrid |e verfasserin |4 aut | |
| 700 | 1 | |a Shelan, Mohamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al |d 1995 |g 198(2022), 10 vom: 22. Okt., Seite 962-965 |w (DE-627)NLM012599174 |x 1439-099X |7 nnns |
| 773 | 1 | 8 | |g volume:198 |g year:2022 |g number:10 |g day:22 |g month:10 |g pages:962-965 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00066-022-01968-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 198 |j 2022 |e 10 |b 22 |c 10 |h 962-965 | ||